Built on a carbohydrate-derived heteropolymer platform with active association complexes formed from poorly absorbable, safe but highly effective compounds, our technology is designed to act locally in the GI tract, minimize systemic exposure, and avoid plastic-like polymer behavior.

This design was selected for safety and biocompatibility. Many important natural and structural polymers in the human body are carbohydrate-based, making the platform conceptually closer to naturally occurring biological polymers than to synthetic plastics. Combined with minimal systemic exposure, this may significantly de-risk development of multiple drug candidates.

Taken as a pill, the platform forms a transient intestinal coating and self-eliminates within hours. This local coating can be engineered to modulate nutrient absorption, receptor activity, ion-channel function, gut-derived hormonal and immune signaling, microbiota interactions, or to provide strong epithelial protection.

By tuning the platform’s physicochemical and compositional properties, we can direct activity toward specific regions of the gut and generate therapeutic candidates across a broad range of GI-driven diseases, including metabolic, inflammatory, functional, and secretory gastrointestinal disorders.